Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.e

Path: ILD with a granulomatous component (see also Im)

With BCG, granulumas can be present in several organs and tissues. See: PMID 7053820

Publications

Birner C, Hackenbroch C, Gagiannis D

Miliary Pneumonia as a Complication of BCG Instillation.

Deutsches Arzteblatt international. 2024;121(2):51

Kaburaki K, Sugino K, Sekiya M, Takai Y, Shibuya K, Homma S

Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy.

Internal medicine (Tokyo, Japan). 2017;56(12):1563-1567

Cho JL, McDermott S, Tsibris AM, Mark EJ

CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 37-2015. A 76-Year-Old Man with Fevers, Leukopenia, and Pulmonary Infiltrates.

The New England journal of medicine. 2015;373(22):2162-72

Tobiume M, Shinohara T, Kuno T, Mukai S, Naruse K, Hatakeyama N, Ogushi F

BCG-induced pneumonitis with lymphocytic pleurisy in the absence of elevated KL-6.

BMC pulmonary medicine. 2014;14:35

Şimşek A, Güler M, Günay S, Çapan N

Miliary tuberculosis after intravesical Bacillus Calmette-Guerin immunotherapy.

Tuberkuloz ve toraks. 2013;61(3):252-4

Delimpoura V, Samitas K, Vamvakaris I, Zervas E, Gaga M

Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy.

BMJ case reports. 2013;2013

Caramori G, Artioli D, Ferrara G, Cazzuffi R, Pasquini C, Libanore M, Guardigni V, Guzzinati I, Contoli M, Rossi R, Rinaldi R, Contini C, Papi A

Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2013;79(1):44-8

Davies B, Ranu H, Jackson M

Pulmonary complications of intravesicular BCG immunotherapy.

Thorax. 2012;67(10):933-4

Um SJ, Lee SK, Yang DK

Hypersensitivity pneumonitis following intravesical bacille Calmette-Guérin immunotherapy for superficial bladder cancer.

Journal of investigational allergology & clinical immunology. 2009;19(3):230-2

Chang H, Klein JS, Norotsky M, Cooper K

Granulomatous chest disease following intravesical bacillus Calmette-Guerin immunotherapy.

Journal of thoracic imaging. 2004;19(1):60-2

Tan L, Testa G, Yung T

Diffuse alveolar damage in BCGosis: a rare complication of intravesical bacillus Calmette-Guérin therapy for transitional cell carcinoma.

Pathology. 1999;31(1):55-6

Rabe J, Neff KW, Lehmann KJ, Mechtersheimer U, Georgi M

Miliary tuberculosis after intravesical bacille Calmette-Guérin immunotherapy for carcinoma of the bladder.

AJR. American journal of roentgenology. 1999;172(3):748-50

Palayew M, Briedis D, Libman M, Michel RP, Levy RD

Disseminated infection after intravesical BCG immunotherapy. Detection of organisms in pulmonary tissue.

Chest. 1993;104(1):307-9

Kristjansson M, Green P, Manning HL, Slutsky AM, Brecher SM, von Reyn CF, Arbeit RD, Maslow JN

Molecular confirmation of bacillus Calmette-Guérin as the cause of pulmonary infection following urinary tract instillation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1993;17(2):228-30

LeMense GP, Strange C

Granulomatous pneumonitis following intravesical BCG. What therapy is needed?

Chest. 1994;106(5):1624-6

Hatzitheofilou C, Obenchain DF, Porter DD, Morton DL

Granulomas in melanoma patients treated with BCG immunotherapy.

Cancer. 1982;49(1):55-60